Y. Wang, L. Meyerson, Y. Tang, and N. Qian. Journal of the neurological sciences, 285 (1-2):
206-11(October 2009)5489<m:linebreak></m:linebreak>JID: 0375403; 0 (Antibodies, Monoclonal); 0 (Immunologic Factors); 0 (natalizumab); 2009/03/05 received; 2009/07/15 revised; 2009/07/22 accepted; 2009/08/25 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Count data.
S. Snapinn, M. Chen, Q. Jiang, and T. Koutsoukos. Pharmaceutical statistics, 5 (4):
273-81(2006)7401<m:linebreak></m:linebreak>LR: 20071115; JID: 101201192; ppublish;<m:linebreak></m:linebreak>Mesures de contrast; RCT.
P. Vavken, K. Heinrich, C. Koppelhuber, S. Rois, and R. Dorotka. Clinical orthopaedics and related research, 467 (12):
3334-9(December 2009)5892<m:linebreak></m:linebreak>LR: 20101202; JID: 0075674; OID: NLM: PMC2772925; 2008/10/17 received; 2009/03/16 accepted; 2009/03/31 aheadofprint; ppublish; Interessant Figura 1 de la relació entre significació estadística i mida de l'efecte<m:linebreak></m:linebreak>Límits de confiança.
H. Brønnum-Hansen. Journal of epidemiology and community health, 53 (5):
300-5(May 1999)4322<m:linebreak></m:linebreak>LR: 20061115; PUBM: Print; JID: 7909766; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.
E. Moodie, and D. Stephens. International journal of public health, 56 (1):
117-9(February 2011)6250<m:linebreak></m:linebreak>GR: Canadian Institutes of Health Research/Canada; JID: 101304551; 2010/05/07 received; 2010/09/12 accepted; 2010/08/01 revised; 2010/10/08 aheadofprint; ppublish;<m:linebreak></m:linebreak>Propensity score; Marginal structural models; Introductori.
O. Amit, R. Heiberger, and P. Lane. Pharmaceutical statistics, 7 (1):
20-35(2008)4522<m:linebreak></m:linebreak>PUBM: Print; CI: (c) 2007; JID: 101201192; ppublish;<m:linebreak></m:linebreak>Presentació de dades.
J. Robins, M. Hernán, and A. Rotnitzky. American journal of epidemiology, 166 (9):
994-1002; discussion 1003-4(November 2007)4950<m:linebreak></m:linebreak>GR: R01-HL080644/HL/NHLBI NIH HHS/United States; GR: R37-AI032475/AI/NIAID NIH HHS/United States; JID: 7910653; CON: Am J Epidemiol. 2007 Nov 1;166(9):985-93. PMID: 17875580; 2007/09/17 aheadofprint; ppublish;.
T. Friede, and H. Schmidli. Statistics in medicine, 29 (10):
1145-56(May 2010)5506<m:linebreak></m:linebreak>JID: 8215016; aheadofprint;<m:linebreak></m:linebreak>Sample size; Count data.
T. Lash, and S. Cole. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (23):
e55-6(August 2009)5436<m:linebreak></m:linebreak>JID: 8309333; 2009/07/13 aheadofprint; ppublish;<m:linebreak></m:linebreak>Mesures d'associació; Immortal time bias.
A. Stang, C. Poole, and O. Kuss. European journal of epidemiology, 25 (4):
225-30(April 2010)5552<m:linebreak></m:linebreak>M3: 10.1007/s10654-010-9440-x;<m:linebreak></m:linebreak>Significació estadística.
H. Janes, L. Sheppard, and K. Shepherd. Annals of epidemiology, 18 (10):
792-802(October 2008)4973<m:linebreak></m:linebreak>JID: 9100013; 0 (Air Pollutants); 2008/01/09 received; 2008/05/17 revised; 2008/06/18 accepted; ppublish;.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
J. Klein, B. Logan, M. Harhoff, and P. Andersen. Statistics in medicine, 26 (24):
4505-19(October 2007)4622<m:linebreak></m:linebreak>CI: Copyright (c) 2007; GR: R01 CA54706-10/CA/NCI NIH HHS/United States; JID: 8215016; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.